Pharmaceutical

Pfizer’s Ngenla finally secures FDA approval following a rocky road to market

Pfizer has announced that the FDA has approved Ngenla (somatrogon-ghla), a paediatric growth hormone deficiency treatment.

Jun 29, 2023 - 20:00
Pfizer’s Ngenla finally secures FDA approval following a rocky road to market
Pfizer has announced that the FDA has approved Ngenla (somatrogon-ghla), a paediatric growth hormone deficiency treatment.
Read the original article

Tags:

Previous Article

Genprex’s Reqorsa gene therapy secures another FDA fast-track designation

Next Article

Cellusion shares pipeline update for eye disease stem cell therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘Underwhelming’: NIH trials fail to test meaningful long Covid treatments — after 2.5 years and $1 billion

‘Underwhelming’: NIH trials fail to test meaningful lon...

Aug 9, 2023

STAT+: Mindpath seemed like a success story for private equity in mental health. Now, it’s a cautionary tale

STAT+: Mindpath seemed like a success story for private...

Apr 19, 2023

FDA says older adults and the immunocompromised may get a spring booster dose of Covid vaccine

FDA says older adults and the immunocompromised may get...

Apr 19, 2023